Advances in long non-coding RNA regulating drug resistance of cancer

Drug resistance is one of the main challenges in cancer treatment. Long non coding RNAs (lncRNAs) play a complex and precise regulatory role in regulating drug resistance of cancer. The common ways of lncRNA regulating drug resistance of cancer involve ATP binding transporter overexpression, abnormal DNA damage response, tumor cell apoptosis, accumulation of epithelial mesenchymal transformation and cancer stem cell formation. Moreover, studies on exosomal lncRNAs regulating cancer drug resistance are developed in recent years. Further study on the role and mechanism of lncRNAs drug resistance in cancer will help clinical cancer treatment program and explore new treatment methods. This paper reviews recent advances in lncRNAs regulating drug resistance of cancer, especially the role of exosomal lncRNAs.

Automated summary

Drug resistance is a major challenge in cancer treatment, and long non-coding RNAs (lncRNAs) play a complex and precise regulatory role in regulating drug resistance in cancer. The common ways in which lncRNAs regulate drug resistance include ATP binding transporter overexpression, abnormal DNA damage response, tumor cell apoptosis, accumulation of epithelial mesenchymal transition, and cancer stem cell formation. Recent developments have focused on the role of exosomal lncRNAs in regulating cancer drug resistance. Further research into the role and mechanisms of lncRNAs in drug resistance in cancer will aid in improving clinical cancer treatment programs and exploring new treatment methods.